Head of Health Economics & Market Access
€110.5k - €175.4k+ Annual bonus + Sales commissions
Senior, Expert
Bachelor's
Norderstedt, Germany
Hybrid
Business & StrategyBusiness Operations
About the job
Requirements
- An advanced degree in health economics, health policy, public health, economics, healthcare management, epidemiology, outcomes research, or another relevant discipline is required.
- Deep expertise in health technology assessment, health economics, reimbursement, and market access, with the judgement to translate technical evidence into strategic business decisions.
- A strong track record of influencing senior internal and external stakeholders and securing alignment in complex, high-stakes environments is required.
- At least 7 years of progressive experience in MedTech, pharmaceuticals, an HTA or payer organisation, healthcare consultancy, academia, outcomes research, or another relevant healthcare-system setting is required, including substantial experience operating at senior strategic level.
- Expert understanding of the German healthcare system, payer landscape, funding pathways, procurement environment, and relevant policy developments is required.
- Demonstrated breadth and depth of market access and health-economics experience, with evidence of leading strategic decisions rather than solely delivering technical work, is required.
- Proven people-leadership experience with direct accountability for building, leading, and developing teams, setting direction, managing performance, coaching senior talent, and succession planning is required.
- Demonstrated executive presence and ability to lead through influence, challenge constructively, and secure decisions across a senior cross-functional matrix is required.
- Strong portfolio leadership and governance capabilities are required, including prioritising competing investments, managing risk, and driving complex programmes to measurable outcomes.
- Ability to critically assess and synthesise clinical and health-economic evidence and convert it into clear executive recommendations and compelling value narratives is required.
- Demonstrated accountability for delivering strategic objectives through cross-functional teams within agreed budgets, timelines, governance, and compliance standards is required.
- Sound judgement, independence, and resilience are required, including the ability to make decisions under ambiguity and take ownership of their consequences.
- Exceptional communication and influencing skills are required, with credibility to represent HEMA with executive leaders, customers, payers, and external institutions.
Responsibilities
- Lead and be accountable for the Germany HEMA department, defining its vision, strategic direction, operating model, and annual priorities in alignment with German and regional business objectives.
- Build, lead, and develop a high-performing team through clear objectives, effective delegation, coaching, succession planning, performance management, and an inclusive culture of accountability.
- Own departmental planning, budget, and resource allocation, making evidence-based trade-offs across portfolio priorities and ensuring delivery against agreed objectives, timelines, and compliance requirements.
- Serve as the senior HEMA adviser to the Germany leadership team, shaping portfolio, investment, evidence, and commercial decisions and clearly communicating risks, strategic options, and recommendations.
- Own the development and execution of differentiated market access strategies for new technologies and established portfolios, with clear objectives, governance, milestones, and measures of impact.
- Set the strategic direction for HEMA tools and value communication, ensuring complex clinical and economic evidence is translated into credible, compliant, and actionable messages for customer-facing teams.
- Establish and sustain senior relationships with payers, healthcare leaders, professional societies, and governmental bodies, representing the organisation on strategic access and policy matters.
- Provide cross-functional leadership across Commercial, Medical, Clinical, Regulatory, and Finance teams to integrate HEMA priorities into portfolio strategy, launch planning, and business execution.
- Shape the evidence-generation strategy for new product development and portfolio growth, identifying and sponsoring local health-economic, outcomes-research, and real-world-evidence initiatives that address priority access gaps.
- Approve and remain accountable for health-economic input into innovative commercial initiatives requiring substantiation of value, including value-based procurement and value-based agreements.
- Maintain governance over the adaptation and local approval of regional HEMA tools, ensuring strategic relevance, methodological quality, compliance, and effective deployment.
- Sponsor the deployment of reimbursement, value, and health-economic solutions with Sales and Marketing, maintaining direct engagement with priority customers and ensuring field insights inform strategy.
Desired Qualifications
- Prior MedTech and German market experience.
- Experience engaging with payers.
- Familiarity with healthcare systems database sources.
- A track record of overcoming complex market access challenges.
- Experience with strategic planning aligned with priority projects to achieve excellence in execution.
- Previous experience developing business cases, value briefs, and value propositions to support market access strategies.
- Experience delivering reimbursement and HTA information to internal sales and marketing teams.
- Ability to critically assess and synthesize clinical, epidemiological, real-world, and health-economic evidence.
About the company
Johnson & Johnson develops prescription medicines and makes medical devices for hospitals, and unlike most big drugmakers, it runs both businesses under one roof. In 2015, its Darzalex became the first antibody drug approved for multiple myeloma, a blood cancer. Its medicines treat cancer, immune diseases such as psoriasis, and mental illnesses such as depression, and patented drugs bring in most of its sales. Its MedTech unit makes heart pumps, catheters that treat irregular heartbeats, surgical sutures, and Acuvue contact lenses. It was founded in 1886 to make sterile surgical dressings, is based in New Brunswick, New Jersey, and spun off its consumer brands, such as Tylenol and Band-Aid, as Kenvue in 2023.
Company Size
10,001+
Company Stage
IPO
Headquarters
New Brunswick, New Jersey
Founded
1886
Get referred to Johnson & Johnson
See people who can refer or advise you
Simplify's Take
What believers are saying
- Cancer drugs drive growth: oncology sales rose 17% to $7.4 billion in the June 2026 quarter, 29% of the total.
- Stock grants have gained value: J&J shares rose 58% in the year to September 2026, versus 23% for Pfizer.
- Students have a way in: J&J listed 1,897 open jobs in October 2026, including 201 internships, co-ops and early-career roles.
What critics are saying
- Its key immune drug trails: AbbVie's Skyrizi outsold Tremfya $5.5 billion to $2.0 billion in the June 2026 quarter.
- Orthopedics is leaving J&J: in September 2026, it was negotiating a $20 billion sale to buyout firm Apollo.
- Baby powder suits remain costly: in July 2026, J&J agreed to pay $5.5 billion to end about 76,000 cancer claims.
What makes Johnson & Johnson unique
- Its debt is rated safer than America's: S&P's top AAA rating goes to only two US companies, J&J and Microsoft.
- Employees rank above shareholders: J&J's 1943 Credo lists duties to patients, then staff and communities, with stockholders last.
- Its psoriasis pill is a first: Icotyde, approved March 2026, blocks an immune signal rivals target only by injection.
Help us improve and share your feedback! Did you find this helpful?
Benefits
- Health Insurance
- Dental Insurance
- Vision Insurance
- Life Insurance
- Disability Insurance
- 401(k) Retirement Plan
- 401(k) Company Match
- Paid Vacation
- Paid Sick Leave
- Paid Holidays
- Remote Work Options
- Performance Bonus